Publication
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerTransitional Cell Carcinomacivic_curation1.00
- drugInfigratinibcivic_curation1.00
- geneTACC3civic_curation1.00
- variantTACC3 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (11)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29848605
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGFR3 F384L1 | ||||||||
| Infigratinib | Transitional Cell Carcinoma | Predictive | C | Does Not Support Sensitivity Response | 2 | submitted | EID6415In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC | civic |
| FGFR3 G370C1 | ||||||||
| Infigratinib | Transitional Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID6414In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC | civic |
| FGFR3 G380R1 | ||||||||
| Infigratinib | Transitional Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID6413In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC | civic |
| FGFR3 L608V1 | ||||||||
| Infigratinib | Transitional Cell Carcinoma | Predictive | C | Supports Resistance | 1 | submitted | EID6407In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC | civic |
| FGFR3 R248C1 | ||||||||
| Infigratinib | Transitional Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID6410In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC | civic |
| FGFR3 S249C1 | ||||||||
| Infigratinib | Transitional Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID6404In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC | civic |
| TACC3 Fusion1 | ||||||||
| Infigratinib | Transitional Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID6409In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC | civic |
| FGFR3 V555L1 | ||||||||
| Infigratinib | Transitional Cell Carcinoma | Predictive | C | Supports Resistance | 3 | submitted | EID6405In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC | civic |
| FGFR3 V555M1 | ||||||||
| Infigratinib | Transitional Cell Carcinoma | Predictive | C | Supports Resistance | 3 | submitted | EID6406In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC | civic |
| FGFR3 Y373C2 | ||||||||
| Infigratinib | Transitional Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID6411In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC | civic |
| 〃 | Transitional Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID6412In this one-arm study, 67 patients with metastastic urothelial carcinoma and diverse FGFR3 alterations were treated with pan-FGFR Inhibitor BGJ398. The majority of patients (70.1%) had received two or… (full text at CIViC) PMID 29848605 · Pal et al., 2018 · Open in CIViC | civic |